Turning liabilities into opportunities: Off-target based drug repurposing in cancer-Reference-Cited by-同舟云学术

Turning liabilities into opportunities: Off-target based drug repurposing in cancer

Published:2021-01 Issue: Volume:68 Page:209-229
ISSN:1044-579X
Container-title:Seminars in Cancer Biology
language:en
Short-container-title:Seminars in Cancer Biology

Author:

Palve Vinayak,Liao Yi,Remsing Rix Lily L.^ORCID,Rix Uwe

Funder

National Cancer Institute

Publisher

Elsevier BV

Subject

Cancer Research

Reference369 articles.

1. Cancer genomics: from discovery science to personalized medicine;Chin;Nat. Med.,2011

2. A new initiative on precision medicine;Collins;N. Engl. J. Med.,2015

3. Genomic and personalized medicine: foundations and applications;Ginsburg;Transl. Res.,2009

4. The path to personalized medicine;Hamburg;N. Engl. J. Med.,2010

5. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts;Baselga;Cancer Res.,1998

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. G–PLIP: Knowledge graph neural network for structure-free protein–ligand bioactivity prediction;Computational and Structural Biotechnology Journal;2024-12

2. DrugMAP 2.0: molecular atlas and pharma-information of all drugs;Nucleic Acids Research;2024-09-13

3. Cancer-associated fibroblasts confer ALK inhibitor resistance inEML4-ALK-driven lung cancer via concurrent integrin and MET signaling;2024-08-28

4. Comprehensive applications of the artificial intelligence technology in new drug research and development;Health Information Science and Systems;2024-08-08

5. Therapeutic Target Identification and Drug Discovery Driven by Chemical Proteomics;Biology;2024-07-23